TABLE 5.

Pharmacokinetic properties of newly approved BLBLIs

Parameter	Value for drug combination by dose ratioa
	4:1 (2.5 g q8h [over 2 h]):		2:1 (1.5 g or 3 g q8h [over 1 h]):		1:1 (4 g q8h [over 3 h]):		2:1 (1.25 g q6h [over 0.5 h]):b
	CAZ	AVI	TOL	TAZ	MER	VAB	IMI	REL
Vss (liter)c	17	22.2	13.5	18.2	20.2	18.6	24.3	19.0
Half-life (h)	2.76	2.71	3.12	1.03	2.3	2.3	1.0	1.2
% protein bound	<10	5.7–8.2	16–21	30	2	33	20	22
AUCELF:fAUCplasmad	0.26–0.31	0.35	0.50	0.62	0.63	0.79	0.55	0.54
CL (ml/min)e
Renal	100	158	57–112	210	130	99	115	123
Total	115	218	68–112	340	175	133	223	133

^aCAZ, ceftazidime; AVI, avibactam; TOL, ceftolozane; TAZ, tazobactam; MER, meropenem; VAB, vaborbactam; IMI, imipenem; REL, relebactam.

^bFormulated as 500 mg imipenem plus 500 mg cilastatin plus 250 mg relebactam.

^cV_ss, volume of distribution at steady state.

^dAUC, area under the curve; ELF, epithelial lining fluid.

^eCL, clearance.